340 filings
6-K
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
6-K
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
GLPG
Galapagos NV
29 Mar 24
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
6:14am
6-K
GLPG
Galapagos NV
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
GLPG
Galapagos NV
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
qj3ivxdb
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
asn1 eql94aabz7yp6l2
4 Jan 24
Current report (foreign)
5:32pm
6-K
spxe edzocpa
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
0f9yqjxzk
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
6-K
lh76s1wjraqf
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
wvlan0mznsyvla
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
1pmjrhgn8 awrz9
12 Dec 23
Current report (foreign)
6:00am
6-K
9iou4
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
56jf0pb s6
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
hqh0gywty5j80
20 Sep 23
Galapagos appoints Simon Sturge to its Board of Directors
6:00am
6-K
xj05jk4s5 s3m
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am
6-K
7z9l1xmw5sqyvu
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
8uncjn09j6 j13
15 Jun 23
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
5:03pm
6-K
2of83qbm
13 Jun 23
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
7:53am
6-K
6fhnk yk7
12 Jun 23
Current report (foreign)
7:32am